UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 28, 2011
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 0-16005 | 22-2328609 | ||
|
(State or other jurisdiction of
|
(Commission | (I.R.S. Employer | ||
| incorporation or organization) | File Number) | Identification No.) |
| 81 Fulton Street, Boonton, New Jersey | 07005 | |||
| (Address of principal executive offices) | (Zip Code) |
(973) 265-1100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 5 – Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Effective October 28, 2011 and November 1, 2011, respectively, Mr. Marvin L. Miller and Mr. Allen Bloom each retired as a director of Unigene Laboratories, Inc. (the “Company”). Board Member Joel A. Tune replaces Mr. Miller as Chairman of the Nominating and Corporate Governance Committee and Board Member Zvi Eiref replaces Mr. Bloom as Chairman of the Audit Committee. Board Member Theron (Ted) Odlaug, Ph.D. is the now Chairman of the Compensation Committee.
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UNIGENE LABORATORIES, INC.
|
||
|
By:
|
/s/ Gregory Mayes
|
|
|
Gregory Mayes, Vice President,
|
||
| Corporate Development & General Counsel | ||
|
Date: November 2, 2011
|
||